Literature DB >> 21841326

Reduction of neuromelanin-positive nigral volume in patients with MSA, PSP and CBD.

Kenichi Kashihara1, Takayoshi Shinya, Fumiyo Higaki.   

Abstract

OBJECTIVE: Diseases presenting extrapyramidal symptoms are accompanied by nigral cell loss. In the previous study, we demonstrated the reduction of the neuromelanin-positive volume of substantia nigra (SN) pars compacta (SNc) in patients with Parkinson's disease (PD) using 3-Tesla MRI. In the present study we investigated the neuromelanin-positive SNc volume in patients with the other parkinsonian disorders including multiple system atrophy (MSA), progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) and compared the results with those with PD, spinocerebellar ataxia (SCA) and controls. PATIENTS AND METHODS: Axial T1-weighted (T1W) images were obtained with a 3-Tesla MRI scanner. The border of the neuromelanin-positive region of the SNc was traced manually on these images with a pentablet pointing device and the SNc volume was calculated. The SNc volumes of 28 patients with MSA, 11 patients with PSP and 10 patients with CBD were compared with those of 80 patients with PD, 9 patients with SCA and 54 patients who had suffered mild acute ischemic stroke as controls. The mean volumes for the left and right SN were used for statistical analyses.
RESULTS: The volumes of the neuromelanin-positive SNc region in patients with MSA, PSP and CBD, but not SCA were reduced to the same extent as PD patients compared with controls.
CONCLUSION: Reduced volume of the neuromelanin-positive SNc region of patients with MSA, PSP and CBD was detected by neuromelanin MR imaging. Volumetric evaluation of neuromelanin MR imaging may provide a biomarker of nigral degeneration in patients with MSA, PSP and CBD as in patients with PD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21841326     DOI: 10.2169/internalmedicine.50.5101

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  18 in total

1.  Correlation between neuromelanin-sensitive MR imaging and (123)I-FP-CIT SPECT in patients with parkinsonism.

Authors:  Keita Kuya; Yuki Shinohara; Fuminori Miyoshi; Shinya Fujii; Yoshio Tanabe; Toshihide Ogawa
Journal:  Neuroradiology       Date:  2016-01-16       Impact factor: 2.804

2.  Significance of apparent diffusion coefficient measurement for the differential diagnosis of multiple system atrophy, progressive supranuclear palsy, and Parkinson's disease: evaluation by 3.0-T MR imaging.

Authors:  Kazumichi Tsukamoto; Eiji Matsusue; Yoshiko Kanasaki; Suguru Kakite; Shinya Fujii; Toshio Kaminou; Toshihide Ogawa
Journal:  Neuroradiology       Date:  2012-01-25       Impact factor: 2.804

3.  Differential effects of intrastriatal 6-hydroxydopamine on cell number and morphology in midbrain dopaminergic subregions of the rat.

Authors:  Michelle Healy-Stoffel; S Omar Ahmad; John A Stanford; Beth Levant
Journal:  Brain Res       Date:  2014-06-09       Impact factor: 3.252

4.  A multicontrast approach for comprehensive imaging of substantia nigra.

Authors:  Jason Langley; Daniel E Huddleston; Xiangchuan Chen; Jan Sedlacik; Nishant Zachariah; Xiaoping Hu
Journal:  Neuroimage       Date:  2015-02-28       Impact factor: 6.556

Review 5.  Magnetic resonance imaging for the diagnosis of Parkinson's disease.

Authors:  Beatrice Heim; Florian Krismer; Roberto De Marzi; Klaus Seppi
Journal:  J Neural Transm (Vienna)       Date:  2017-04-04       Impact factor: 3.575

6.  Correlation between pathology and neuromelanin MR imaging in Parkinson's disease and dementia with Lewy bodies.

Authors:  Shinichiro Kitao; Eiji Matsusue; Shinya Fujii; Fuminori Miyoshi; Toshio Kaminou; Shinsuke Kato; Hisao Ito; Toshihide Ogawa
Journal:  Neuroradiology       Date:  2013-05-15       Impact factor: 2.804

7.  Pool size ratio of the substantia nigra in Parkinson's disease derived from two different quantitative magnetization transfer approaches.

Authors:  Paula Trujillo; Paul E Summers; Alex K Smith; Seth A Smith; Luca T Mainardi; Sergio Cerutti; Daniel O Claassen; Antonella Costa
Journal:  Neuroradiology       Date:  2017-10-06       Impact factor: 2.804

Review 8.  MRI biomarkers of motor and non-motor symptoms in Parkinson's disease.

Authors:  Sephira G Ryman; Kathleen L Poston
Journal:  Parkinsonism Relat Disord       Date:  2019-10-10       Impact factor: 4.891

Review 9.  Nigrosome Imaging and Neuromelanin Sensitive MRI in Diagnostic Evaluation of Parkinsonism.

Authors:  Nicola Pavese; Yen F Tai
Journal:  Mov Disord Clin Pract       Date:  2018-02-22

10.  Neuromelanin-sensitive magnetic resonance imaging: a promising technique for depicting tissue characteristics containing neuromelanin.

Authors:  Ken Nakamura; Keizo Sugaya
Journal:  Neural Regen Res       Date:  2014-04-01       Impact factor: 5.135

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.